Cell Therapeutics, Inc. (CTIC: Quote) on Tuesday said the University of Washington's School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy, or RT, to the combination of temozolomide, or TMZ, and RT for patients with newly-diagnosed glioblastoma multiforme.
The study objective is to determine whether paclitaxel poliglumex and RT are likely to improve progression-free survival and overall survival compared to TMZ and RT. It will also evaluate neuro-cognitive function and toxicities of these therapies.
Glioblastoma multiforme or GBM is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT, which substantially decreases the effectiveness of standard therapy with TMZ.
This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group in Providence, Rhode Island. The first patient at UW recently has been enrolled.
by RTT Staff Writer
For comments and feedback: email@example.com